Complement-specific antibodies: designing novel anti-inflammatories.
作者信息
Matis L A, Rollins S A
机构信息
Immunobiology Program, Alexion Pharmaceuticals, Inc., New Haven, Connecticut 06511, USA.
出版信息
Nat Med. 1995 Aug;1(8):839-42. doi: 10.1038/nm0895-839.
Abstract
摘要
相似文献
1
Complement-specific antibodies: designing novel anti-inflammatories.补体特异性抗体：设计新型抗炎药。
Nat Med. 1995 Aug;1(8):839-42. doi: 10.1038/nm0895-839.
2
Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody.抗体工程技术生成长效抗 C5 再循环抗体 SKY59。
PLoS One. 2018 Dec 28;13(12):e0209509. doi: 10.1371/journal.pone.0209509. eCollection 2018.
3
From functions to mechanisms of the prototypic complement C5 antibody BB5.1.从原型补体C5抗体BB5.1的功能到作用机制
Immunology. 2020 Oct;161(2):81-82. doi: 10.1111/imm.13261.
4
Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass.抗C5补体抗体培塞利珠单抗对接受体外循环心脏手术患者的总死亡率和不良心血管结局的影响。
Ann Thorac Surg. 2004 Mar;77(3):942-9; discussion 949-50. doi: 10.1016/j.athoracsur.2003.08.054.
5
Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.用针对补体成分C5的阻断性单克隆抗体治疗后，NZB/WF1小鼠狼疮样自身免疫病得到改善。
Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8563-8. doi: 10.1073/pnas.93.16.8563.
6
Monoclonal antibodies directed against human C5 and C8 block complement-mediated damage of xenogeneic cells and organs.针对人类C5和C8的单克隆抗体可阻断补体介导的异种细胞和器官损伤。
Transplantation. 1995 Dec 15;60(11):1284-92.
7
In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5.一种识别人类C5的单链Fv片段在体外和体内对补体活性的抑制作用
Mol Immunol. 1995 Nov;32(16):1183-95. doi: 10.1016/0161-5890(95)00099-2.
8
C5 neoepitopes appearing during activation.激活过程中出现的C5新表位。
Complement Inflamm. 1989;6(3):219-22. doi: 10.1159/000463095.
9
Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass.重组人源化单链抗体C5补体抑制剂在接受体外循环冠状动脉搭桥手术患者中的药理学及生物学效应
Circulation. 1999;100(25):2499-506. doi: 10.1161/01.cir.100.25.2499.
10
Effect of anti-C5 antibody on recuperation from ischemia/reperfusion-induced acute kidney injury.抗 C5 抗体对缺血/再灌注诱导的急性肾损伤恢复的影响。
Ren Fail. 2019 Nov;41(1):967-975. doi: 10.1080/0886022X.2019.1677248.
引用本文的文献
1
Shiga Toxin-Producing E. coli and Hemolytic Uremic Syndrome: A Study of the 2022 Outbreak in Turkey.产志贺毒素大肠杆菌与溶血尿毒综合征：2022年土耳其疫情研究
Med Sci Monit. 2024 Dec 9;30:e946033. doi: 10.12659/MSM.946033.
2
Application of eculizumab, a terminal complement inhibitor, in the management of atypical hemolytic uremic syndrome in a 14-month-old Chinese pediatric patient: a case report.终末补体抑制剂依库珠单抗在一名14个月大中国儿科患者非典型溶血性尿毒症综合征治疗中的应用：一例报告
Front Pediatr. 2024 Jul 31;12:1404725. doi: 10.3389/fped.2024.1404725. eCollection 2024.
3
Anti-complement 5 antibody ameliorates antibody-mediated rejection after liver transplantation in rats.抗补体 5 抗体可改善大鼠肝移植后抗体介导的排斥反应。
Front Immunol. 2023 Jun 16;14:1186653. doi: 10.3389/fimmu.2023.1186653. eCollection 2023.
4
Exploiting protease activation for therapy.利用蛋白酶激活进行治疗。
Drug Discov Today. 2022 Jun;27(6):1743-1754. doi: 10.1016/j.drudis.2022.03.011. Epub 2022 Mar 18.
5
Emerging Role of C5 Complement Pathway in Peripheral Neuropathies: Current Treatments and Future Perspectives.C5补体途径在周围神经病变中的新作用：当前治疗方法与未来展望
Biomedicines. 2021 Apr 7;9(4):399. doi: 10.3390/biomedicines9040399.
6
Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study.依库珠单抗作为重症监护病房中成年重症 COVID-19 患者的紧急治疗：一项概念验证研究。
EClinicalMedicine. 2020 Nov;28:100590. doi: 10.1016/j.eclinm.2020.100590. Epub 2020 Nov 5.
7
Complement-targeted therapy: development of C5- and C5a-targeted inhibition.补体靶向治疗：C5和C5a靶向抑制的发展
Inflamm Regen. 2016 Jun 3;36:11. doi: 10.1186/s41232-016-0013-6. eCollection 2016.
8
Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape.阵发性睡眠性血红蛋白尿中的补体：利用我们目前的知识改善治疗前景。
Expert Rev Hematol. 2014 Oct;7(5):583-98. doi: 10.1586/17474086.2014.953926. Epub 2014 Sep 2.
9
The discovery of medicines for rare diseases.罕见病药物的发现。
Future Med Chem. 2014 Jun;6(9):987-1002. doi: 10.4155/fmc.14.65.
10
Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going.阵发性睡眠性血红蛋白尿症的抗补体治疗：我们的现状与未来走向
Transl Med UniSa. 2014 Feb 4;8:43-52. eCollection 2014 Jan.
本文引用的文献
1
In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5.一种识别人类C5的单链Fv片段在体外和体内对补体活性的抑制作用
Mol Immunol. 1995 Nov;32(16):1183-95. doi: 10.1016/0161-5890(95)00099-2.
2
Immunosuppressive therapy as a determinant of transplantation outcomes.
Transplantation. 1993 Jun;55(6):1297-305. doi: 10.1097/00007890-199306000-00017.
3
"Diabodies": small bivalent and bispecific antibody fragments.“双抗体”：小型双价双特异性抗体片段。
Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6444-8. doi: 10.1073/pnas.90.14.6444.
4
Membrane signaling by complement C5b-9, the membrane attack complex.补体膜攻击复合物C5b-9介导的膜信号传导
Immunol Res. 1993;12(3):244-57. doi: 10.1007/BF02918256.
5
beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain.β-淀粉样蛋白通过与C1q A链胶原样结构域的特定区域结合来激活补体。
J Immunol. 1994 May 15;152(10):5050-9.
6
Antigen-specific human antibodies from mice comprising four distinct genetic modifications.来自小鼠的具有四种不同基因修饰的抗原特异性人类抗体。
Nature. 1994 Apr 28;368(6474):856-9. doi: 10.1038/368856a0.
7
Direct selection for a catalytic mechanism from combinatorial antibody libraries.从组合抗体文库中直接筛选催化机制。
Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2532-6. doi: 10.1073/pnas.91.7.2532.
8
Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs.利用人Ig重链和轻链酵母人工染色体构建的小鼠产生的抗原特异性人单克隆抗体。
Nat Genet. 1994 May;7(1):13-21. doi: 10.1038/ng0594-13.
9
Clinical complementology: recent progress and future trends.临床补体学：最新进展与未来趋势
Eur J Clin Invest. 1994 Apr;24(4):219-28. doi: 10.1111/j.1365-2362.1994.tb01078.x.
10
Making antibodies by phage display technology.利用噬菌体展示技术制备抗体。
Annu Rev Immunol. 1994;12:433-55. doi: 10.1146/annurev.iy.12.040194.002245.
Zotero 插件